Drugs for Treating Congestive Heart Failure: Global Markets
The global market for congestive heart failure pharmaceuticals was valued at nearly $11.2 billion in 2010. This market is expected to reach nearly $12.2 billion in 2011 and $18.6 billion in 2016, a compound annual growth rate (CAGR) of 8.9% between 2011 and 2016.
SCOPE OF STUDY
This report is a comprehensive business tool designed to provide an in-depth look at drugs for the congestive heart failure market. The geographic scope of the report is global with a special emphasis on individual regions. The report describes the industry, its relationship to the healthcare industry and its participants, and trends for the future.
Categories discussed in the report include:
- Angiotensin converting enzyme (ACE) inhibitors/angiotensin II receptor blocker antagonists (ARBs)
- Beta-adrenergic receptor blocking agents
- Inotropic drugs/vasodilators
All categories are discussed in detail, describing each segment, identifying current products on the market, measuring market size, identifying market drivers, forecasting for 2010 to 2016, and assessing the competitors and competitor market shares.
Mary Anne Crandall is an expert industry analyst specializing in the pharmaceutical industry for the last 20 years. She has completed several in-depth studies on various medical topics requiring both medical expertise and excellent knowledge of the pharmaceutical industry. Ms. Crandall has extensive knowledge in the medical field, has an M.S. in psychology, and is currently working on a PhD.